Recent research into burnout in primary care providers has found many providers experience professional dissonance and cite increasing paperwork and undervaluation as contributors to burnout. The study also outlined solutions that may improve professional fulfillment…
Editor’s note: It is with much sadness that we learned this morning that Paul Caplan, MD, passed away yesterday, March 7, 2020. “He was a remarkable person who continued to celebrate life up to the end,” says Terence W. Starz, MD, University of Pittsburgh School of Medicine. “He had a great caring, wisdom, and commitment…
The evidence-based guideline includes contraceptive recommendations and suggestions for rheumatologists co-managing patients with obstetrician-gynecologists and other specialists.
(Reuters Health)—Sports physicians routinely prescribe corticosteroids to athletes for conditions, such as inflammation, asthma and allergies, but not all of them know which forms of these drugs are banned under anti-doping rules, a study suggests. The survey of 603 physicians from 30 countries found four in five prescribe oral corticosteroids to athletes, one of the…
In a recent study, olokizumab proved safe and effective for treating the signs and symptoms of RA and improving patients’ physical function…
GCA, GPA, myositis, new research—rheumatology care keeps clinicians on their toes & requires them to stay up to date…
How does a patient transition from health to active SLE? This question is the crux of the research conducted by Judith A. James, MD, PhD, and colleagues…
NEW YORK (Reuters Health)—Low-dose methotrexate can be associated with gastrointestinal, pulmonary, infectious, hematologic and other adverse effects, according to an analysis of the Cardiovascular Inflammation Reduction Trial (CIRT). “Methotrexate is not a benign drug, even at dosages used for rheumatic diseases,” Daniel H. Solomon, MD, MPH of Brigham and Women’s Hospital, Boston, tells Reuters Health…
FDA advisory committees rejected the new drug application for oxycodegol, an opioid analgesic, due to a lack of data regarding it’s potential for abuse…
Recent research assessed the risk of gout in patients with type 2 diabetes mellitus prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with those prescribed a glucagon-like peptide-1 (GLP-1) agonist. The study found patients on the SGLT2 inhibitor had a lower rate of gout, suggesting SGLT2 inhibitors may actually reduce the risk of gout among this patient population…